Fullerene

1. What conditions has Fullerene been studied for?

• Cancer (therapy, targeted delivery, and theranostics): Multiple studies describe fullerene derivatives as antitumor agents and/or as drug delivery platforms for cancer treatment, including photodynamic therapy and magnetic targeting.

• Inflammatory and allergic skin disease (atopic dermatitis model): A water-soluble C60 dispersion (nC60) was tested in a mouse model of atopic dermatitis with epicutaneous and subcutaneous administration.

• Inflammatory diseases more broadly (immune modulation): One review notes fullerene derivatives explored as antioxidants for inflammatory diseases and reports immune effector cell stabilization to reduce proinflammatory mediator release (with examples including asthma, arthritis, and multiple sclerosis as potential targets).

• Neuroinflammation / Parkinson’s disease (PD): An abstract states neuroinflammation is a driver in PD and describes exploring “anti-neuroinflammatory fullerenes” as a therapeutic strategy.

• Viral infections:

  • HIV-1: Specific fullerene derivatives were tested in human CD4(+) T cells and affected late-stage virion maturation.

  • Ebola (model system): Mannosylated “fullerene sugar balls” showed antiviral activity in an Ebola pseudotyped infection model.

  • COVID-19 (drug discovery target mentioned): One abstract frames SARS-CoV-2 main protease as a target; however, the provided text is truncated and does not clearly report fullerene efficacy results.

• Bacterial infection (anti-adhesion concept): Glycofullerenes are described as potential anti-adhesive agents against bacterial infection via lectin binding (“glycoside cluster effect”).

• Dermatology/cosmetics (skin antioxidant use and safety): A review discusses fullerene in skin care products for antioxidant capacity and also summarizes toxicity concerns toward skin cells.

• Imaging/diagnostics: Endohedral fullerenes (e.g., gadolinium-containing) are discussed as MRI contrast agents; a C60-iron oxide-PEG composite is described as a T2 MRI contrast agent in vivo.

2. Does it work in treating those conditions? Summarize the evidence.

• Atopic dermatitis (mouse model): Evidence of benefit in vivo. In BALB/c mice with ovalbumin-induced dermatitis, water-soluble nC60 given subcutaneously (0.1 mg/kg) or epicutaneously (1 mg/kg) over a 50-day period produced:

  • Significant suppression of IgE and Th2 cytokines, with increased Th1 cytokines.

  • Increased Foxp3(+) and filaggrin mRNA expression (noted with epicutaneous application), consistent with immune regulation and improved skin barrier markers.

  • Histologic improvement with reduced eosinophil/leukocyte infiltration; epicutaneous treatment was reported as more effective than subcutaneous.

  Limitations: animal model; does not establish efficacy or safety in humans.

• Cancer (photodynamic therapy + targeting; mouse tumor model): Evidence of enhanced antitumor activity in vitro and in vivo for a specific engineered system. A C60-IONP-PEG nanocomposite conjugated to hematoporphyrin monomethyl ether (HMME) showed:

  • “Remarkably enhanced” photodynamic cancer cell killing in cultured B16-F10 cells (in vitro).

  • Enhanced effect in an in vivo murine tumor model, attributed to magnetic targeting and strong photodynamic activity.

  • Reported 23-fold higher tumor uptake of HMME compared with free HMME.

  Limitations: this supports a delivery/targeting advantage in preclinical models; it does not prove clinical benefit in humans, and results may not generalize to other fullerene forms.

• HIV-1 (cell-based evidence): Two fullerene derivatives showed strong antiviral activity in human CD4(+) T cells by disrupting late-stage virion maturation:

  • Viruses produced in the presence of the compounds lacked infectivity despite unremarkable RNA packaging and viral production.

  • Gag and Gag-Pol processing was affected; virion-associated reverse transcriptase activity supported impaired maturation.

  • Notably, the compounds did not inhibit HIV-1 protease in vitro at effective doses, suggesting a protease-independent mechanism, and they blocked infection by HIV-1 resistant to protease and maturation inhibitors.

  Limitations: ex vivo/in vitro cellular evidence; no human clinical outcomes provided.

• Ebola (pseudotyped infection model): Mannosylated glycofullerenes showed antiviral activity in an Ebola pseudotyped infection model.

  Limitations: pseudotyped model is not the same as clinical Ebola infection; no animal/human efficacy shown in the study.

• Neuroinflammation / Parkinson’s disease: One abstract indicates exploration of “anti-neuroinflammatory fullerenes” as a strategy for PD, but the provided text does not include outcomes, effect sizes, or model details.

• Inflammatory diseases (asthma, arthritis, multiple sclerosis): A review states certain fullerene derivatives can stabilize immune effector cells and prevent/inhibit proinflammatory mediator release, positioning them as candidates for these diseases. This is suggestive but not definitive evidence of clinical efficacy.

• MRI contrast / theranostics: Reviews discuss gadolinium-containing endohedral fullerenes as MRI contrast agents, and the C60-IONP-PEG system is described as usable as a T2 contrast agent in vivo. These are diagnostic/theranostic applications rather than “treatment” efficacy.

3. What health benefits does it have?

• Potential anti-inflammatory and immunomodulatory effects: In the atopic dermatitis mouse model, nC60 reduced IgE and Th2 cytokines, increased Th1 cytokines, increased Foxp3(+) and filaggrin mRNA, and reduced inflammatory cell infiltration—consistent with reduced allergic inflammation and improved barrier-related markers.

• Antioxidant-related applications: A dermatology/cosmetics-focused review notes fullerene’s “exceptional antioxidant capacity,” which is a rationale for inclusion in skin care products (though antioxidant capacity does not automatically translate to clinical benefit).

• Anticancer utility via drug delivery and photodynamic therapy enhancement: The C60-IONP-PEG/HMME system improved tumor uptake (23-fold) and enhanced photodynamic cancer cell killing in vitro and in a murine tumor model, suggesting fullerene-based platforms may improve delivery/targeting and therapeutic index in some contexts.

• Antiviral activity (preclinical): Specific fullerene derivatives inhibited HIV-1 infectivity in human CD4(+) T cells by impairing virion maturation, including activity against strains resistant to protease and maturation inhibitors (cell-based evidence).

• Anti-adhesion approach for bacterial infection (conceptual/preclinical): Glycofullerenes (“sugar balls”) are described as potential anti-adhesive agents against bacterial infection through multivalent lectin binding.

• Diagnostic/theranostic potential: Reviews describe endohedral fullerenes (e.g., gadolinium-containing) as MRI contrast candidates, and a C60-iron oxide-PEG composite is described as a T2 MRI contrast agent alongside therapeutic photodynamic capability.

4. Does it have any downsides or side effects?

• Toxicity depends strongly on the derivative and formulation: Several studies emphasize that “properly modified” fullerene nanoparticles can have improved biocompatibility, implying that unmodified or certain modified forms may have limitations.

• Cationic toxicity (limits some anticancer aminated derivatives): One abstract explicitly states aminated fullerene derivatives have promising antitumor effects but their in vivo applications are “severely limited due to cation toxicity.” It describes using human heavy chain ferritin (HFn) to improve biocompatibility via supramolecular assembly.

• Potential for skin cell toxicity/dermal reactions: A review on fullerene in skin care products notes that while fullerene is used for antioxidant purposes, it also has “potentials to display a range of activities resulting in cell death or dysfunction,” and it summarizes reports assessing toxicity toward skin cells and possible dermal reactions.

• General translational uncertainties: Multiple items are reviews or preclinical studies (cell culture, mouse models). Human safety, long-term biodistribution, and clinically relevant adverse effects are not established in the studies reviewed here.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The studies reviewed here do not report pharmacogenomic findings (i.e., no specific human genetic variants predicting response, toxicity, metabolism, or dosing requirements for fullerene or fullerene derivatives).

• No variant-specific efficacy or safety data: The evidence described is primarily mechanistic, in vitro, or animal-model based, without genotype-stratified outcomes.

• Resistance context is viral, not human pharmacogenomics: One HIV-1 study reports activity against HIV-1 strains resistant to protease and maturation inhibitors, but this reflects viral resistance mutations rather than human genetic variation.

References

1. Fullerene-based delivery systems.
   Houman Kazemzadeh, Masoud Mozafari (2019) - Drug discovery today
2. Ferritin-Based Supramolecular Assembly Drug Delivery System for Aminated Fullerene Derivatives to Enhance Tumor-Targeted Therapy.
   Baoli Zhang, Libin Yang, Yiliang Jin, Yicheng Lu, Jianru Li, Guoheng Tang, Yang Liu, Jiawei Huo, Ran Xu, Chunru Wang, Xiyun Yan, Jie Li, Kelong Fan (2025) - Advanced science (Weinheim, Baden-Wurttemberg, Germany)
3. Mesoporous carbon nanomaterials in drug delivery and biomedical application.
   Qinfu Zhao, Yuanzhe Lin, Ning Han, Xian Li, Hongjian Geng, Xiudan Wang, Yu Cui, Siling Wang (2017) - Drug delivery
4. PEGylated fullerene/iron oxide nanocomposites for photodynamic therapy, targeted drug delivery and MR imaging.
   Jinjin Shi, Xiaoyuan Yu, Lei Wang, Yan Liu, Jun Gao, Jing Zhang, Rou Ma, Ruiyuan Liu, Zhenzhong Zhang (2013) - Biomaterials
5. Research progress of fullerenes and their derivatives in the field of PDT.
   Xue Bai, Chungeng Dong, Xinle Shao, Faiz-Ur Rahman, Huifang Hao, Yongmin Zhang (2024) - European journal of medicinal chemistry
6. Fullerene nanoparticle in dermatological and cosmetic applications.
   S Zeinab Mousavi, Shohreh Nafisi, Howard I Maibach (2017) - Nanomedicine : nanotechnology, biology, and medicine
7. Synthesis and biological application of glyco- and peptide derivatives of fullerene C
   Lisa Tanzi, Marco Terreni, Yongmin Zhang (2022) - European journal of medicinal chemistry
8. Application of fullerenes in nanomedicine: an update.
   Anthony Dellinger, Zhiguo Zhou, James Connor, A B Madhankumar, Sarala Pamujula, Christie M Sayes, Christopher L Kepley (2013) - Nanomedicine (London, England)
9. Oral [60]fullerene reduces neuroinflammation to alleviate Parkinson's disease via regulating gut microbiome.
   Xue Li, Ruijun Deng, Jie Li, Hui Li, Zhe Xu, Lei Zhang, Linyin Feng, Chunying Shu, Mingming Zhen, Chunru Wang (2023) - Theranostics
10. Theoretical Insight into Complexation Between Cyclocarbons and C
    Zeyu Liu, Tian Lu (2024) - Chemistry (Weinheim an der Bergstrasse, Germany)
11. Recent advances in nanocarrier-loaded gels: Which drug delivery technologies against which diseases?
    Marion Pitorre, Henri Gondé, Clotilde Haury, Marwa Messous, Jérémie Poilane, David Boudaud, Erdem Kanber, Glenn Alexis Rossemond Ndombina, Jean-Pierre Benoit, Guillaume Bastiat (2017) - Journal of controlled release : official journal of the Controlled Release Society
12. Antitumor Activity and Potential Mechanism of Novel Fullerene Derivative Nanoparticles.
    Lianjie Ye, Larwubah Kollie, Xing Liu, Wei Guo, Xiangxian Ying, Jun Zhu, Shengjie Yang, Meilan Yu (2021) - Molecules (Basel, Switzerland)
13. Fullerene sugar balls: a new class of biologically active fullerene derivatives.
    Iwona Nierengarten, Jean-François Nierengarten (2014) - Chemistry, an Asian journal
14. Anti-inflammatory effect of fullerene C60 in a mice model of atopic dermatitis.
    Nadezda Shershakova, Elena Baraboshkina, Sergey Andreev, Daria Purgina, Irina Struchkova, Oleg Kamyshnikov, Alexandra Nikonova, Musa Khaitov (2016) - Journal of nanobiotechnology
15. Fullerene Derivatives Strongly Inhibit HIV-1 Replication by Affecting Virus Maturation without Impairing Protease Activity.
    Zachary S Martinez, Edison Castro, Chang-Soo Seong, Maira R Cerón, Luis Echegoyen, Manuel Llano (2016) - Antimicrobial agents and chemotherapy
16. Fullerenes for cancer diagnosis and therapy: preparation, biological and clinical perspectives.
    Zhiyun Chen, Ruoqing Mao, Ying Liu (2012) - Current drug metabolism
17. Biocompatibility, antioxidant activity and collagen photoprotection properties of C
    Vladimir V Sharoyko, Olga S Shemchuk, Anatolii A Meshcheriakov, Lubov V Vasina, Nailia R Iamalova, Michail D Luttsev, Daria A Ivanova, Andrey V Petrov, Dmitriy N Maystrenko, Oleg E Molchanov, Konstantin N Semenov (2022) - Nanomedicine : nanotechnology, biology, and medicine
18. Fullerene derivatives as inhibitors of the SARS-CoV-2 main protease.
    Daiki Katagishi, Daisuke Yasuda, Kyoko Takahashi, Shigeo Nakamura, Tadahiko Mashino, Tomoyuki Ohe (2023) - Bioorganic & medicinal chemistry letters
19. Analysis of Biomechanical Parameters of Muscle Soleus Contraction and Blood Biochemical Parameters in Rat with Chronic Glyphosate Intoxication and Therapeutic Use of C
    Dmytro Nozdrenko, Olga Abramchuk, Svitlana Prylutska, Oksana Vygovska, Vasil Soroca, Kateryna Bogutska, Sergii Khrapatyi, Yuriy Prylutskyy, Peter Scharff, Uwe Ritter (2021) - International journal of molecular sciences

This article summarizes published research for educational purposes. It is not medical advice. Talk to your doctor before starting, stopping, or changing any supplement or medication.